Which has higher valuation and earnings, RGEN or TECH?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 13.22 $48.89M $0.73 236.86 Bio-Techne $1.22B 9.34 $181.86M $1.15 62.90

Is RGEN or TECH more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 5.29% 5.30% 3.79% Bio-Techne 14.97% 13.23% 10.61%

Does the media favor RGEN or TECH?

In the previous week, Bio-Techne had 5 more articles in the media than Repligen. MarketBeat recorded 13 mentions for Bio-Techne and 8 mentions for Repligen. Repligen's average media sentiment score of 1.23 beat Bio-Techne's score of 1.18 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor A or TECH?

In the previous week, Bio-Techne had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 13 mentions for Bio-Techne and 10 mentions for Agilent Technologies. Bio-Techne's average media sentiment score of 1.18 beat Agilent Technologies' score of 0.87 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or BIO?

In the previous week, Bio-Techne had 8 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 13 mentions for Bio-Techne and 5 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.49 beat Bio-Techne's score of 1.18 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or CRL?

In the previous week, Bio-Techne had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 13 mentions for Bio-Techne and 7 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.18 beat Charles River Laboratories International's score of 1.07 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TECH or DHR?

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.34 $181.86M $1.15 62.90 Danaher $24.57B 5.96 $3.61B $5.63 37.03

Is TECH or DHR more profitable?

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Danaher 15.95% 11.04% 6.81%

Does the media prefer TECH or DHR?

In the previous week, Danaher had 5 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Danaher and 13 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.18 beat Danaher's score of 1.09 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 8 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Bio-Techne (TECH) Competitors

$72.33 -0.01 (-0.01%)

Closing price 04:00 PM Eastern

Extended Trading

$72.30 -0.03 (-0.04%)

As of 06:02 PM Eastern

Compare

TECH vs. RGEN, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? Bio-Techne's main competitors and comparable companies include Repligen (RGEN), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Techne compare to Repligen?

Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	13.22	$48.89M	$0.73	236.86
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.90

Repligen has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Repligen presently has a consensus price target of $168.57, suggesting a potential downside of 2.51%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.71%. Given Repligen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

97.6% of Repligen shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Bio-Techne	14.97%	13.23%	10.61%

In the previous week, Bio-Techne had 5 more articles in the media than Repligen. MarketBeat recorded 13 mentions for Bio-Techne and 8 mentions for Repligen. Repligen's average media sentiment score of 1.23 beat Bio-Techne's score of 1.18 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Agilent Technologies has a net margin of 19.53% compared to Bio-Techne's net margin of 14.97%. Agilent Technologies' return on equity of 24.45% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Bio-Techne	14.97%	13.23%	10.61%

In the previous week, Bio-Techne had 3 more articles in the media than Agilent Technologies. MarketBeat recorded 13 mentions for Bio-Techne and 10 mentions for Agilent Technologies. Bio-Techne's average media sentiment score of 1.18 beat Agilent Technologies' score of 0.87 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.23	$1.30B	$5.08	30.21
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.90

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.7%. Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Agilent Technologies currently has a consensus target price of $170.33, suggesting a potential upside of 11.00%. Bio-Techne has a consensus target price of $68.92, suggesting a potential downside of 4.71%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agilent Technologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Summary

Agilent Technologies beats Bio-Techne on 13 of the 20 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Bio-Techne currently has a consensus target price of $68.92, suggesting a potential downside of 4.71%. Bio-Rad Laboratories has a consensus target price of $343.33, suggesting a potential downside of 9.44%. Given Bio-Techne's higher possible upside, equities research analysts clearly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.90
Bio-Rad Laboratories	$2.58B	3.92	$759.90M	$8.25	45.95

Bio-Techne has a net margin of 14.97% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Techne's return on equity of 13.23% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

In the previous week, Bio-Techne had 8 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 13 mentions for Bio-Techne and 5 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.49 beat Bio-Techne's score of 1.18 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.90
Charles River Laboratories International	$4.02B	3.25	-$144.34M	-$4.85	N/A

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.3% of Bio-Techne shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bio-Techne presently has a consensus price target of $68.92, suggesting a potential downside of 4.71%. Charles River Laboratories International has a consensus price target of $265.69, suggesting a potential downside of 2.91%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Bio-Techne had 6 more articles in the media than Charles River Laboratories International. MarketBeat recorded 13 mentions for Bio-Techne and 7 mentions for Charles River Laboratories International. Bio-Techne's average media sentiment score of 1.18 beat Charles River Laboratories International's score of 1.07 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Charles River Laboratories International on 9 of the 15 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Bio-Techne (NASDAQ:TECH) and Danaher (NYSE:DHR) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.90
Danaher	$24.57B	5.96	$3.61B	$5.63	37.03

In the previous week, Danaher had 5 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Danaher and 13 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.18 beat Danaher's score of 1.09 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	8 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Danaher	15.95%	11.04%	6.81%

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 10.8% of Danaher shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Danaher pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has raised its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bio-Techne has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Danaher has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Bio-Techne currently has a consensus target price of $68.92, suggesting a potential downside of 4.71%. Danaher has a consensus target price of $228.91, suggesting a potential upside of 9.81%. Given Danaher's stronger consensus rating and higher possible upside, analysts plainly believe Danaher is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Danaher	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Danaher beats Bio-Techne on 12 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.34B	$10.29B	$7.19B	$14.92B
Dividend Yield	0.44%	1.47%	2.57%	11.71%
P/E Ratio	62.90	67.95	274.09	25.35
Price / Sales	9.34	108.64	697.83	112.39
Price / Cash	30.78	26.23	77.71	51.48
Price / Book	5.37	5.46	10.37	6.25
Net Income	$181.86M	$56.67B	$3.49B	$358.55M
7 Day Performance	0.11%	1.52%	-1.78%	-2.07%
1 Month Performance	-0.10%	1.74%	-1.48%	-4.80%
1 Year Performance	39.69%	26.00%	18.20%	5.44%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	3.3217 of 5 stars	$72.33 0.0%	$68.92 -4.7%	+40.1%	$11.34B	$1.22B	62.90	3,000	Positive News
RGEN Repligen	2.9773 of 5 stars	$167.60 flat	$166.43 -0.7%	+53.6%	$9.46B	$738.26M	229.59	2,000	Positive News
A Agilent Technologies	4.3544 of 5 stars	$150.60 -0.2%	$170.33 +13.1%	+19.7%	$42.53B	$6.95B	29.65	18,100
BIO Bio-Rad Laboratories	1.8261 of 5 stars	$386.26 +0.0%	$343.33 -11.1%	+34.6%	$10.32B	$2.58B	46.82	7,450	Positive News
CRL Charles River Laboratories International	2.1692 of 5 stars	$289.40 +0.3%	$255.65 -11.7%	+79.0%	$13.77B	$4.02B	N/A	19,700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Which has higher valuation and earnings, RGEN or TECH?

Which has more volatility and risk, RGEN or TECH?

Do analysts rate RGEN or TECH?

Do institutionals and insiders believe in RGEN or TECH?

Is RGEN or TECH more profitable?

Does the media favor RGEN or TECH?

Summary

How does Bio-Techne compare to Agilent Technologies?

Is A or TECH more profitable?

Does the media favor A or TECH?

Which has more risk and volatility, A or TECH?

Which has better earnings and valuation, A or TECH?

Is A or TECH a better dividend stock?

Do institutionals and insiders believe in A or TECH?

Do analysts prefer A or TECH?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Do analysts recommend TECH or BIO?

Which has more risk and volatility, TECH or BIO?

Which has higher earnings & valuation, TECH or BIO?

Is TECH or BIO more profitable?

Does the media prefer TECH or BIO?

Do insiders & institutionals hold more shares of TECH or BIO?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Which has more risk and volatility, TECH or CRL?

Which has higher valuation and earnings, TECH or CRL?

Do insiders and institutionals hold more shares of TECH or CRL?

Do analysts rate TECH or CRL?

Is TECH or CRL more profitable?

Does the media prefer TECH or CRL?

Summary

How does Bio-Techne compare to Danaher?

Which has preferable earnings & valuation, TECH or DHR?

Does the media prefer TECH or DHR?

Is TECH or DHR more profitable?

Do insiders and institutionals have more ownership in TECH or DHR?

Is TECH or DHR a better dividend stock?

Which has more volatility & risk, TECH or DHR?

Do analysts rate TECH or DHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools